Mivacurium (Mivacron, The Wellcome Foundation Ltd, Crewe, Cheshire, UK) is a recently introduced short-acting, non-depolarizing muscle relaxant. Like the depolarizing muscle relaxant suxamethonium, the termination of its clinical effect is largely dependent on metabolism by plasma cholinesterase.' Unlike suxamethonium, which acts by mimicking the action of acetylcholine and thus depolarizing the motor end-plate at the post-synaptic receptor, mivacurium acts by competing with acetylcholine for the cholinergic receptors on the motor end-plates, thus inhibiting the effects of acetylcholine. This means that the neuromuscular blocking effects of mivacurium can theoretically be reversed by administration of anticholinesterases such as neostigmine, and this has indeed been reported.i-' It is not clear whether anticholinesterases can inhibit plasma cholinesterase (and hence, mivacurium metabolism) as well as acetylcholinesterase.
In individuals who have plasma cholinesterase variants, there are conflicting reports on whether or not the prolonged neuromuscular block resulting from plasma cholinesterase deficiency can be reversed by anticholinesterases.v"
We present a patient with plasma cholinesterase deficiency due to the presence of a combination of the atypical and silent plasma cholinesterase genes (phenotype AS), who suffered prolonged neuromuscular block and apnoea following administration of mivacurium. This was not successfully reversed by administration of neostigmine.
Correspondence: W S Robertson.
CASE HISTORY
The patient was a 44-year-old woman admitted as a day case for a laparoscopic tubal clip procedure. Pre-operatively her blood pressure was 110170 mm Hg, pulse rate SO/min, and weight 49 kg. Cardiovascular and respiratory systems were normal and there was no previous history of general anaesthesia.
Pre-medication diclofenac sodium (50 mg) and metoclopramide (10 mg) were given orally 1 h 30 min before surgery. Anaesthesia was induced through a 20 gauge Yenflon needle with 50 p.g fentanyl, 200 mg propofol and 15 mg lignocaine plain (11170 solution) added to avoid any pain.
A laryngeal mask (No.3) was inserted, followed by an injection of 6 mg mivacurium (0-12 mg/kg). Maintenance was with oxygen (1-5 L), nitrous oxide (3 L) and isofluorane (1%) through a closed circle system. Intermittent positive pressure ventilation (IPPY) was commenced with an Oxford Penlon ventilator. Routine monitoring was used. A further dose of mivacurium (2 mg) was given after 15 min because it was felt that the patient was not fully relaxed. The entire procedure took 25 minutes from the time of induction.
Post-operatively there was no sign of recovery and no respiratory effort. Neostigmine (2' 5 mg) and glycopyrronium (0' 5 mg) were given by injection without effect. The laryngeal mask was replaced by an endotracheal tube and IPPY commenced with oxygen (3 L) and nitrous oxide (3 L) using a Manley ventilator. A 5% dextrose drip (I L) was also commenced.
After 3 h of ventilation the patient started to breathe, moved her limbs and tried to pull out her endotracheal tube. The ventilator was switched off and the patient allowed to breathe spontaneously through a Bain circuit for a further 15 min. She was extubated when she was fully conscious and her breathing was satisfactory. Since the introduction of mivacurium into clinical practice, some reports of neuromuscular block in patients with plasma cholinesterase deficiency due to the presence of variants have been published.
Our patient showed a similar response to those reported by Peterson et al? and Lightrnan" in that administration of neostigmine did not successfully reverse the block. Like our patient, that of Lightrnan" had the AS plasma cholinesterase phenotype. Peterson's patient was reported as having either the AA or AS phenotype.
It seems possible that in the reported cases of prolonged neuromuscular block in patients homozygous for the atypical plasma cholinesterase gene, those with the AA phenotype may respond to anticholinesterase (such as neostigmine) while those with the AS phenotype may not. Several variants of the silent gene have been described'<" which may also explain differences in response to anticholinesterases between individuals who are assigned the same or similar phenotypes.
In conclusion, it is important that patients presenting with mivacurium sensitivity should be investigated for plasma cholinesterase phenotype in the same way as those presenting with the more widely recognized suxamethonium sensitivity. If appropriate, family studies should be carried out and individuals at risk should be issued with warning cards which indicate that they may be sensitive to both suxamethonium and mivacurium. After transfer to the recovery ward for observation overnight, she was discharged the following morning, at which time she had no muscle weakness. The total period of apnoea from induction to recovery was 3 h 15 min.
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Three days after surgery, blood was collected for serum cholinesterase determination and phenotyping. Blood was also collected from the patient's sole surviving parent (her mother) and from her sister.
Serum cholinesterase was determined by the method of Kalow and Lindsay, 7 in which the rate of hydrolysis of the substrate benzoylcholine is measured by monitoring absorbance change at 240 nm. Either serum or heparinized plasma is suitable for use in the assay. Phenotyping was achieved by the use of the four differential inhibitors, dibucaine, sodium fluoride, dimethylcarbamate of 2-hydroxy-5-phenylbenzyltrimethylammonium bromide (R02-0683) and pancuronium bromide dibutyrate (PBr Dibutyrate) incorporated into the assay system.v '! Results are shown in Table 1 . Serum cholinesterase and inhibitor number determination cannot with certainty differentiate between the UU and US phenotypes, nor between the AA and AS phenotypes. In this case, however, the phenotypes can be predicted since the mother does not carry the atypical gene (A) and neither the patient nor her sister carries the usual gene (U). The mother must therefore have the phenotype US, and both the patient and her sister must have the phenotype AS. 
